Is Egrifta (Tesamorelin) Legal in Georgia? How to Access It Legally
See the public record for Tesamorelin
At a glance
- FDA status / Approved prescription biologic, BLA 022505, first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current products / Egrifta SV 2 mg vial, 1.4 mg daily; Egrifta WR 11.6 mg vial, 1.28 mg daily; not substitutable [2][3]
- Marketing status / Listed by FDA as a prescription product [1]
- Compounding / In no category of the FDA lists for bulk substances, state-licensed pharmacies or outsourcing facilities [4][5][6]
- Athletes / Prohibited at all times under WADA section S2.2.4 [7]
What FDA has approved
Egrifta's application is BLA 022505, a former new drug application deemed a biologic license application on March 23, 2020, held by Theratechnologies, with an original approval date of November 10, 2010 [1]. Two formulations are currently labeled: Egrifta SV (2 mg vial, 1.4 mg once daily) and Egrifta WR (11.6 mg vial, 1.28 mg once daily). Both labels are dated July 29, 2026, and the labels say the two are not substitutable [2][3].
The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label states that long-term cardiovascular safety has not been established and that the drug is not indicated for weight loss management because its effect on weight is neutral [2].
Can tesamorelin be compounded?
FDA has made no category-based statement about compounding tesamorelin. It appears in no category on FDA's list of bulk substances that may present significant safety risks (content dated 04/22/2026), its list for state-licensed pharmacies and physicians (updated May 14, 2026) or its list for outsourcing facilities (updated March 21, 2025) [4][5][6]. It is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [8][9]. Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [9].
What the labels list as contraindications and monitoring
Both labels contraindicate tesamorelin in people with disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. In rat studies, hydrocephalus occurred in offspring at roughly two to four times the clinical exposure [2].
The label's main monitoring targets are IGF-1 and glucose. Among patients treated 26 weeks in the trials, 47% had IGF-1 above 2 SDS and 36% above 3 SDS. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2].
If the patient is an athlete
WADA's Prohibited List names tesamorelin in S2.2.4 as a growth hormone-releasing factor, prohibited at all times, in and out of competition, and it stays on the 2027 List [7][10].
The Georgia part
FDA approval, the prescription-only status and the label contents above are federal. Georgia-specific requirements for prescribing, telehealth and dispensing are outside what this page covers.
Questions worth asking
Frequently asked questions
Is Egrifta (tesamorelin) legal in Georgia?
Do I need a prescription for tesamorelin?
What is tesamorelin approved to treat?
Can tesamorelin be compounded?
What does the label say to monitor?
References
Show all 10 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Official web page.
- Official web page.
- World Anti-Doping Agency.